Targets › RNASE1
1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout May 2027.
Endonuclease that catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides. Acts on single-stranded and double-stranded RNA. (UniProt, P07998)
Open in Phaseline: the race on RNASE1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Resolve Therapeutics | RSLV-132 Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to hu | RNASE1 | Phase 2 | Primary Sjögren Syndrome | May 2027 |
Primary Sjögren Syndrome (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.